Developing and translating into clinical practice a novel multidimensional treatment paradigm based on nanoparticle delivery systems will have a major positive impact on the clinical management of multiple myeloma. To achieve this long term goal will require thorough characterization of the particles, rigorous control of experimental protocols and careful analysis of experiments results to establish safety and efficacy. The primary mission of Core 2: Data Management is to capture, curate, manage, distribute and facilitate the analysis of all data generated by the CMMN research teams. Core 2 will also provide a suite of collaboration tools for the team and be the primary conduit for data sharing. Currently no facility or core exists at Washington University with the capability to manage the diverse types of data that will be produced by the three research teams that comprise the CMMN. We will build on our decades of experience with large- scale clinical trials and multi-site, multi-disciplinary cancer research teams and our existing base of big data management tools and procedures to meet the data management needs of the CMMN. Currently no coherent strategy for managing nanomaterial characterization exists at WUSTL. While a pre-clinical image management system does exits, it is outdated and does not meet the needs of the CMMN team. To facilitate this translational research and share our processes and experiences with the CMMN cancer research community, we propose to:1) Support all project teams by managing essential protocol and sample characterization information, 2) Capture pre-clinical images generated by all projects, and 3) Integrate all activities of the CMMN team and make information publicly accessible. Our multi-disciplinary Data Management Core team has worked together with the PIs in a similar capacity on prior successful large-scale cancer research projects and networks (4). We have extensive experience with the creation and management of large-scale information repositories and advanced imaging informatics. The long-term goal of our team is to develop and deploy software and services to drive advanced quantitative image analysis, facilitate the development of novel, nanotechnology based cancer therapies and provide a gateway for researchers to interrogate multi-modality datasets and mine them to create and validate novel hypotheses in cancer research. We possess both the biomedical knowledge and informatics skills to facilitate a successful CCNE research agenda.

Public Health Relevance

The primary mission of Core 2: Data Management is to capture, curate, manage, distribute and facilitate the analysis of all data generated by the CMMN research teams. Core 2 will also provide a suite of collaboration tools for the team and be the primary conduit for data sharing. Currently no facility or core exists at Washington University with the capability to manage the diverse types of data that will be produced by the three research teams that comprise the CMMN.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
1U54CA199092-01
Application #
8962045
Study Section
Special Emphasis Panel (ZCA1-TCRB-Q (M1))
Project Start
Project End
Budget Start
2015-09-01
Budget End
2016-08-31
Support Year
1
Fiscal Year
2015
Total Cost
$88,867
Indirect Cost
$28,151
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Ye, Dezhuang; Zhang, Xiaohui; Yue, Yimei et al. (2018) Focused ultrasound combined with microbubble-mediated intranasal delivery of gold nanoclusters to the brain. J Control Release 286:145-153
Miller, Jessica; Wang, Steven T; Orukari, Inema et al. (2018) Perfusion-based fluorescence imaging method delineates diverse organs and identifies multifocal tumors using generic near-infrared molecular probes. J Biophotonics 11:e201700232
Ye, Dezhuang; Sultan, Deborah; Zhang, Xiaohui et al. (2018) Focused ultrasound-enabled delivery of radiolabeled nanoclusters to the pons. J Control Release 283:143-150
Karakocak, Bedia Begum; Liang, Jue; Biswas, Pratim et al. (2018) Hyaluronate coating enhances the delivery and biocompatibility of gold nanoparticles. Carbohydr Polym 186:243-251
de la Puente, Pilar; Luderer, Micah J; Federico, Cinzia et al. (2018) Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma. J Control Release 270:158-176
White, Brian S; Lanc, Irena; O'Neal, Julie et al. (2018) A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J 8:35
Cui, Grace; Akers, Walter J; Scott, Michael J et al. (2018) Diagnosis of LVAD Thrombus using a High-Avidity Fibrin-Specific 99mTc Probe. Theranostics 8:1168-1179
Hathi, Deep K; DeLassus, Elizabeth N; Achilefu, Samuel et al. (2018) Imaging Melphalan Therapy Response in Preclinical Extramedullary Multiple Myeloma with 18F-FDOPA and 18F-FDG PET. J Nucl Med 59:1551-1557
Ghai, Anchal; Maji, Dolonchampa; Cho, Nicholas et al. (2018) Preclinical Development of CD38-Targeted [89Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma. J Nucl Med 59:216-222
Ghobadi, Armin; Rettig, Michael P; Holt, Matthew S et al. (2018) Ixazomib, an oral proteasome inhibitor, induces rapid mobilization of hematopoietic progenitor cells in mice. Blood 131:2594-2596

Showing the most recent 10 out of 61 publications